EMPagliflozin after Aortic Valve Replacement - the EMPAVR study - a randomized clinical trial

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504731-40-01

Acronym

2023-504731-40-00

Enrollment

206

Registered

2023-11-08

Start date

2024-02-07

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic stenosis

Brief summary

Change in left ventricular mass indexed to body surface area (measured by CT) from pre aortic valve replacement (AVR) to 12-months post-AVR

Detailed description

Left ventricular end-systolic volume indexed to body surface are (LVESVi measured by CT), Left ventricular global longitudinal strain (LV GLS) (measured by echo), NT-proBNP change from baseline to 12 months, Composite of death and readmission for any non-planned cause

Interventions

DRUGGlucosemonohydrate with HPMC capsule

DRUGJardiance 10 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in left ventricular mass indexed to body surface area (measured by CT) from pre aortic valve replacement (AVR) to 12-months post-AVR	—

Secondary

Measure	Time frame
Left ventricular end-systolic volume indexed to body surface are (LVESVi measured by CT), Left ventricular global longitudinal strain (LV GLS) (measured by echo), NT-proBNP change from baseline to 12 months, Composite of death and readmission for any non-planned cause	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026